Case Study: Alnylam Pharmaceuticals achieves enhanced site engagement, patient safety, and enrollment in rare-disease trials with IQVIA Investigator Site Portal

Alnylam Puts Sites and Patients First with IQVIA Technologies Investigator Site Portal

Alnylam Pharmaceuticals, a leader in RNAi therapeutics, needed to run patient-centric rare‑disease trials where every participant and investigator relationship mattered. To improve site collaboration, communication, transparency and patient safety across complex protocols, Alnylam implemented the IQVIA Investigator Site Portal from IQVIA in 2014 as a centralized, site‑facing platform.

IQVIA delivered the Investigator Site Portal plus services — site activation, learning management, document exchange, Pre‑ID logs, real‑time surveys (>85% response rates during COVID) and custom tools such as a Blood Volume Calculator — to streamline workflows and reduce manual burden. The solution cut CRA workload, reduced protocol deviations, improved recruitment visibility and patient safety, and supported Alnylam’s rapid development and approvals (including OXLUMO/lumasiran in 2020) over the six‑year partnership with IQVIA.

Alnylam Pharmaceuticals